BR112022011564A2 - Compostos e uso dos mesmos para o tratamento da deficiência de a1-antitripsina - Google Patents
Compostos e uso dos mesmos para o tratamento da deficiência de a1-antitripsinaInfo
- Publication number
- BR112022011564A2 BR112022011564A2 BR112022011564A BR112022011564A BR112022011564A2 BR 112022011564 A2 BR112022011564 A2 BR 112022011564A2 BR 112022011564 A BR112022011564 A BR 112022011564A BR 112022011564 A BR112022011564 A BR 112022011564A BR 112022011564 A2 BR112022011564 A2 BR 112022011564A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- treatment
- antitrypsin deficiency
- antitrypsin
- deficiency
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 title abstract 3
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 abstract 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 abstract 1
- 150000003936 benzamides Chemical class 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSTOS E USO DOS MESMOS PARA O TRATAMENTO DA DEFICIÊNCIA DE a1-ANTITRIPSIN. A invenção refere-se a compostos de benzamida especificados de fórmula (1) e a composições farmacêuticas que contêm os compostos. Os compostos podem ser indutores de a1-antitripsina (A1AT), e podem ser usados no tratamento de uma doença ou distúrbio, como deficiência de a1-antitripsina (A1AD ou AATD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1918416.7A GB201918416D0 (en) | 2019-12-13 | 2019-12-13 | Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency |
| PCT/GB2020/053196 WO2021116710A1 (en) | 2019-12-13 | 2020-12-11 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011564A2 true BR112022011564A2 (pt) | 2022-08-30 |
Family
ID=69186871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011564A BR112022011564A2 (pt) | 2019-12-13 | 2020-12-11 | Compostos e uso dos mesmos para o tratamento da deficiência de a1-antitripsina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230093755A1 (pt) |
| EP (1) | EP4073068B1 (pt) |
| JP (1) | JP2023506201A (pt) |
| KR (1) | KR20220127825A (pt) |
| CN (1) | CN115003669B (pt) |
| AU (1) | AU2020400334A1 (pt) |
| BR (1) | BR112022011564A2 (pt) |
| CA (1) | CA3164304A1 (pt) |
| ES (1) | ES2980046T3 (pt) |
| GB (1) | GB201918416D0 (pt) |
| IL (1) | IL293833A (pt) |
| MX (1) | MX2022007220A (pt) |
| WO (1) | WO2021116710A1 (pt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2114141A2 (en) | 2007-01-10 | 2009-11-11 | University of Florida | Compounds and methods for treatment of alpha-1 antitrypsin deficiency |
| AU2019289228B2 (en) | 2018-06-22 | 2024-11-14 | Ucl Business Ltd | Novel compounds |
| KR20210089656A (ko) | 2018-10-05 | 2021-07-16 | 버텍스 파마슈티칼스 인코포레이티드 | 알파-1 항트립신 조절제 |
| UY38696A (es) | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
-
2019
- 2019-12-13 GB GBGB1918416.7A patent/GB201918416D0/en not_active Ceased
-
2020
- 2020-12-11 IL IL293833A patent/IL293833A/en unknown
- 2020-12-11 ES ES20828097T patent/ES2980046T3/es active Active
- 2020-12-11 CN CN202080094475.5A patent/CN115003669B/zh active Active
- 2020-12-11 JP JP2022535756A patent/JP2023506201A/ja active Pending
- 2020-12-11 MX MX2022007220A patent/MX2022007220A/es unknown
- 2020-12-11 KR KR1020227024025A patent/KR20220127825A/ko active Search and Examination
- 2020-12-11 EP EP20828097.4A patent/EP4073068B1/en active Active
- 2020-12-11 WO PCT/GB2020/053196 patent/WO2021116710A1/en unknown
- 2020-12-11 AU AU2020400334A patent/AU2020400334A1/en not_active Abandoned
- 2020-12-11 BR BR112022011564A patent/BR112022011564A2/pt unknown
- 2020-12-11 CA CA3164304A patent/CA3164304A1/en active Pending
-
2022
- 2022-06-13 US US17/839,246 patent/US20230093755A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL293833A (en) | 2022-08-01 |
| KR20220127825A (ko) | 2022-09-20 |
| GB201918416D0 (en) | 2020-01-29 |
| ES2980046T3 (es) | 2024-09-27 |
| US20230093755A1 (en) | 2023-03-23 |
| MX2022007220A (es) | 2022-09-07 |
| AU2020400334A1 (en) | 2022-07-28 |
| EP4073068B1 (en) | 2024-04-24 |
| WO2021116710A1 (en) | 2021-06-17 |
| JP2023506201A (ja) | 2023-02-15 |
| CN115003669A (zh) | 2022-09-02 |
| CN115003669B (zh) | 2024-10-25 |
| EP4073068A1 (en) | 2022-10-19 |
| CA3164304A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| BR112017012327A8 (pt) | benzamidas substituídas por 1,3-tiazol-2-il. | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
| BR112022009938A2 (pt) | Compostos macrocíclicos substituídos e métodos de tratamento relacionados | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| CY1115588T1 (el) | Αναστολεις ανθρωπινης πρωτεϊνικης φωσφατασης τυροσινης-β και η φαρμακευτικη χρηση τους | |
| BR112022002059A2 (pt) | Formas sólidas de um inibidor de hpk1 | |
| BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112022007612A2 (pt) | Inibidores de raf quinases | |
| BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
| BR112022018667A2 (pt) | Composições e métodos para inibir a expressão de ang-ptl3 | |
| BR112022019492A2 (pt) | Inibidores de rip1k | |
| BR112022021381A2 (pt) | Compostos para o tratamento de sars | |
| BR112016030730A8 (pt) | composto | |
| BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
| BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112022011566A2 (pt) | Compostos e uso dos mesmos para o tratamento de deficiência de a1-antitripsina | |
| BR112022011548A2 (pt) | Compostos e uso dos mesmos para o tratamento da deficiência de a1-antitripsina | |
| BR112018072740A2 (pt) | realçador de inibidores de homólogo 2 de zeste | |
| BR112022011527A2 (pt) | Compostos e uso dos mesmos para o tratamento de deficiência de a1-antitripsina | |
| BR112017028616A2 (pt) | acentuador de inibidores de homólogo de zeste 2 | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |